2021
DOI: 10.1111/pcn.13299
|View full text |Cite
|
Sign up to set email alerts
|

Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations

Abstract: Aim This systematic review identified and thematically appraised clinical evidence of movement disorders in patients with Rett syndrome (RTT). Method Using PRISMA criteria, six electronic databases were searched from inception to April 2021. A thematic analysis was then undertaken on the extracted data to identify potential themes. Results Following the thematic analysis, six themes emerged: (i) clinical features of abnormal movement behaviors; (ii) mutational profile and its impact on movement disorders; (iii… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 14 publications
(9 citation statements)
references
References 135 publications
(344 reference statements)
0
9
0
Order By: Relevance
“…5 Management depends on the severity and etiology of agitation, with options for acute treatment including antihistamines and/or benzodiazepines. 5,6 Antipsychotics are "first line" for maintenance pharmacological therapy for severe agitation or agitation related to neurodevelopmental disorders. 8 Other monotherapy options include clonidine and N-acetylcysteine, both of which are theorized to reduce excitatory signaling that may contribute to aggressive behavior.…”
Section: Discussion Of Case and Literaturementioning
confidence: 99%
See 2 more Smart Citations
“…5 Management depends on the severity and etiology of agitation, with options for acute treatment including antihistamines and/or benzodiazepines. 5,6 Antipsychotics are "first line" for maintenance pharmacological therapy for severe agitation or agitation related to neurodevelopmental disorders. 8 Other monotherapy options include clonidine and N-acetylcysteine, both of which are theorized to reduce excitatory signaling that may contribute to aggressive behavior.…”
Section: Discussion Of Case and Literaturementioning
confidence: 99%
“…8 Other monotherapy options include clonidine and N-acetylcysteine, both of which are theorized to reduce excitatory signaling that may contribute to aggressive behavior. 5,8 Trofinetide is a novel, investigational drug currently awaiting FDA approval that shows promise in targeting the core symptom domains of RTT. 7…”
Section: Discussion Of Case and Literaturementioning
confidence: 99%
See 1 more Smart Citation
“…Hence, potential gene therapies related to TSC were also searched for. To make the search as expansive as possible, we also searched for gene therapies and other disorders using the methodology described previously [26]. In brief, snowballing was used so that as much of the literature related to gene therapy studies could be traced as possible.…”
Section: Primary Search Strategymentioning
confidence: 99%
“…After the period of regression, eye contact improves, but spoken language and purposeful use of the hands are often severely reduced. Individuals with RTT may develop a range of comorbidities and clinical characteristics including episodes of laughing or crying spells (Neul et al, 2010), epilepsy (Glaze et al, 2010; Henriksen et al, 2018), sleep disturbances (Wong et al, 2015), and severe movement disorders (Singh et al, 2021). Gross motor function is also affected but to differing degrees, thus some can walk independently, some with assistance, while others are wheelchair bound.…”
Section: Introductionmentioning
confidence: 99%